Fact Meets Function

KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.

Researchers investigated carrier-free nanoparticles formed by self-assembly of KPV (a tripeptide) and RAPA (rapamycin) as a potential therapeutic approach for vascular calcification in an in vitro study. The findings demonstrated that these self-assembled nanodrugs effectively inhibited calcification markers in cell-based models without requiring synthetic delivery vehicles. This is an in vitro evidence level study and does not provide human clinical data.

KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy. Read Post »

Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro.

Researchers investigated whether glycyl-L-histidyl-L-lysine (GHK), a tripeptide, could prevent protein aggregation and cell death caused by excess copper and zinc in cultured central nervous system cells (in vitro study). The study found that GHK demonstrated protective effects against both copper- and zinc-induced protein aggregation and cellular toxicity in these cell culture models. This is in vitro evidence and does not establish clinical efficacy in human subjects.

Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro. Read Post »

The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.

This in vitro study examined the effects of two growth hormone secretagogues—ipamorelin and GH-releasing peptide-6—on bone mineral content in adult female rats. The researchers found that both compounds increased bone mineral content in the animal models tested. As an in vitro study, these findings represent preliminary laboratory evidence and have not yet been validated in human clinical trials.

The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Read Post »

Ipamorelin, the first selective growth hormone secretagogue.

Ipamorelin was evaluated as a selective growth hormone secretagogue in in vitro studies, demonstrating its ability to selectively stimulate growth hormone release through specific receptor mechanisms. This in vitro research established ipamorelin’s biochemical selectivity compared to other growth hormone secretagogues available at that time. As an in vitro study, these findings demonstrate receptor-level activity but do not provide evidence regarding systemic effects or clinical outcomes in human subjects.

Ipamorelin, the first selective growth hormone secretagogue. Read Post »

Scroll to Top